Overview
Treatment options for patients with unresectable head and neck cancer have been significantly expanded over the last few years. Combined modality treatment with concomitant chemotherapy and radiotherapy represents the standard of care for patients with advanced head and neck cancer and the introduction of new molecular targeted therapies lead to a further improvement in treatment outcomes. This activity will offer the opportunity to learn from a recognized and experienced multidisciplinary team current therapeutic options for patients with advanced and metastatic head and neck cancer. Effective interaction between the multidisciplinary team and participants will be encouraged through clinical case discussion and practical sessions dedicated to treatment planning and delivery.

Learning objectives
By attending this live educational course, participants will be able to:
- Define the methodology of the multidisciplinary approach in the clinical management of head and neck cancer patients
- Review current and novel therapeutic approaches for the treatment of head and neck cancer patients
- Recognize the importance of supportive care in the treatment of patients with head and neck cancer

Target audience
Medical oncologists, surgeons and radiation oncologists coming from Asia, who are experienced in managing head and neck cancer (HNC) patients and whose interest is to broaden their understanding of the multidisciplinary team approach and the current therapeutic options for patients with advanced and metastatic HNC. A good command of the English language is essential.

Chair
Makoto Tahara
Head and Neck Oncology Division
National Cancer Center Hospital East
Kashiwa, Japan
CME Provider

EXCEMED is a non profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world.

EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME®) which states that continuing medical education must be balanced, independent, objective, and scientifically rigorous.

EXCEMED adheres to the principles of the Good CME Practice group (gCMEp).
This live educational course takes place at:

**National Cancer Center Hospital East**
Kashiwa, Chiba Prefecture, Japan

**Language**
The official language of this live educational course will be English.
Simultaneous translation from Japanese to English and vice-versa will be provided.

**CME Provider**
EXCEMED - Excellence in Medical Education
Programme and Relations Manager: Serena Dell’Ariccia
T +39 06 420413 251 - F +39 06 420413 677
serena.dellariccia@excemed.org
Medical Advisor: Cristina Raimondi
cristina.raimondi@libero.it
Faculty

Guest speaker

Jan Baptiste Vermorken
Department of Medical Oncology
Antwerp University Hospital
Edegem, Belgium

National Cancer Center Hospital East, Kashiwa, Japan

Tetsuo Akimoto
Radiation Oncology Division

Ryuichi Hayashi
Head and Neck Surgery Division

Tetsuhito Konishi
Department of Dentistry

Reiko Matsui
Pharmacy Division

Susumu Okano
Head and Neck Oncology Division

Minoru Sakuraba
Plastic and Reconstructive Surgery Division

Shinya Suzuki
Pharmacy Division

Makoto Tahara
Head and Neck Oncology Division

Sadamoto Zenda
Radiation Oncology Division
### Programme

**Monday, 5 December 2016**

<table>
<thead>
<tr>
<th>Session I</th>
<th>Role of the MDT in the clinical management of HNC patients: benefits from MDT</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.45</td>
<td>Welcome and opening</td>
</tr>
<tr>
<td></td>
<td><strong>Lessons</strong></td>
</tr>
<tr>
<td>9.00</td>
<td>Multidisciplinary team (MDT) in the treatment of head and neck cancer (HNC)</td>
</tr>
<tr>
<td></td>
<td>M. Tahara (Japan)</td>
</tr>
<tr>
<td>9.20</td>
<td>Role of head and neck surgeon in MDT</td>
</tr>
<tr>
<td></td>
<td>R. Hayashi (Japan)</td>
</tr>
<tr>
<td>9.40</td>
<td>Role of medical oncologist in MDT</td>
</tr>
<tr>
<td></td>
<td>M. Tahara (Japan)</td>
</tr>
<tr>
<td>10.00</td>
<td>Role of radiation oncologist in MDT</td>
</tr>
<tr>
<td></td>
<td>T. Akimoto (Japan)</td>
</tr>
<tr>
<td>10.20</td>
<td>Role of reconstructive surgeon in MDT</td>
</tr>
<tr>
<td></td>
<td>M. Sakuraba (Japan)</td>
</tr>
<tr>
<td>10.50</td>
<td>Coffee Break</td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11.10</td>
<td>How to optimize an MDT for head and neck cancer patients: open discussion between experts and audience</td>
</tr>
<tr>
<td></td>
<td>M. Tahara (Japan) J.B. Vermorken (Belgium)</td>
</tr>
<tr>
<td>11.30</td>
<td>Case discussion: from the National Cancer Center Hospital East</td>
</tr>
<tr>
<td></td>
<td>S. Zenda (Japan)</td>
</tr>
<tr>
<td></td>
<td><strong>In practice</strong></td>
</tr>
<tr>
<td></td>
<td>How to manage the toxicities in outpatient clinic</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.30</td>
<td>Improved infrastructure for outpatient clinic</td>
</tr>
<tr>
<td></td>
<td>M. Tahara (Japan)</td>
</tr>
<tr>
<td>14.30</td>
<td>Oral care</td>
</tr>
<tr>
<td></td>
<td>T. Konishi (Japan)</td>
</tr>
<tr>
<td>14.50</td>
<td>Role of pharmacist in outpatient clinic</td>
</tr>
<tr>
<td></td>
<td>R. Matsui (Japan)</td>
</tr>
<tr>
<td>15.10</td>
<td>Improving patient adherence by using flowchart type leaflet</td>
</tr>
<tr>
<td></td>
<td>S. Suzuki (Japan)</td>
</tr>
<tr>
<td>15.30</td>
<td>End of the first day</td>
</tr>
</tbody>
</table>

**Session II**

**Case discussions**

11.10 - 11.30: How to optimize an MDT for head and neck cancer patients: open discussion between experts and audience

M. Tahara (Japan)
J.B. Vermorken (Belgium)

13.30 - 13.50: Case discussion: from the National Cancer Center Hospital East

S. Zenda (Japan)

14.30 - 15.00: Improved infrastructure for outpatient clinic

M. Tahara (Japan)

15.10 - 15.30: Role of pharmacist in outpatient clinic

R. Matsui (Japan)

15.30 - 16.00: Improving patient adherence by using flowchart type leaflet

S. Suzuki (Japan)

16.00: End of the first day
Tuesday, 6 December 2016

### Session II
**How to introduce evidence to daily clinical practice**

<table>
<thead>
<tr>
<th>Time</th>
<th>Lessons</th>
<th>Case discussions</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Role of evidence-based medicine&lt;br&gt; M. Tahara (Japan)</td>
<td>14.00  How to introduce evidence to daily clinical practice&lt;br&gt; M. Tahara (Japan)</td>
</tr>
<tr>
<td>9.20</td>
<td>Review of NEW guidance for HNC – overview of Japanese and international available guidelines&lt;br&gt; S. Okano (Japan)&lt;br&gt; S. Zenda (Japan)</td>
<td>16.00  Coffee break</td>
</tr>
<tr>
<td>11.00</td>
<td>Coffee break</td>
<td>16.30  Multidisciplinary weekly head and neck cancer conference</td>
</tr>
<tr>
<td>11.30</td>
<td>Impact of tumor HPV status on outcome and treatment strategies in patients with head and neck cancers&lt;br&gt; J.B. Vermorken (Belgium)</td>
<td>17.30  End of the second day</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td>Immunotherapy for HNC&lt;br&gt; M. Tahara (Japan)</td>
<td></td>
</tr>
</tbody>
</table>
Wednesday, 7 December 2016

Session III: Patient quality of life

Lessons

HNC treatment and improved quality of life

9.00  Conservative surgery
      (including partial laryngectomy and hypopharyngectomy)
      R. Hayashi (Japan)

9.30  Optimizing approaches in radiation therapy
      (including IMRT and proton beam therapy)
      T. Akimoto (Japan)

10.00 Treatment indication; elderly patients, comorbidity
     J.B. Vermorken (Belgium)

Lessons

Management of toxicities & complications

10.30 Chemotherapy toxicities and nutrition care
      S. Okano (Japan)

11.00 Coffee break

11.30 Radiation dermatitis
      S. Zenda (Japan)

12.00 Surgical complication
      R. Hayashi (Japan)

12.30 Lunch

Novel therapeutic approaches for HNC

13.30 Keynote lecture:
      Biologic therapy in head and neck cancer: a road with hurdles
      J.B. Vermorken (Belgium)

14.30 Coffee break

15.00 The importance of informed consent: open discussion between experts and audience
      M. Tahara (Japan)

16.30 Tour to view:
      Outpatient clinic
      ➢ Department of Head and Medical oncology
      ➢ Department of Radiation oncology
      ➢ Department of Head and Neck surgical oncology
      ➢ Division of Pharmacy
      ➢ Outpatient care center

      Inpatient clinic
      ➢ Tour of the groups

18.30 End of the live educational course
Disclosure of faculty relationships

EXCEM ED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEM ED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Tetsuo Akimoto
Declared no potential conflict of interest.

Reiko Matsui
Declared no potential conflict of interest.

Susumu Okano
Declared the receipt of honoraria as speakers from Merck.

Shinya Suzuki
Declared no potential conflict of interest.

Makoto Tahara
Declared the receipt of grants and contracts from Eisai, MSD, Boehringer Ingelheim, AstraZeneca, Ono, Novartis, Bayer, NanoCarrier, Pfizer. He declared also the receipt of honoraria or consultation fees from Merck, MSD, BMS, Eisai, Otuska, AstraZeneca, Pfizer. He declared to be member of MSD, Boehringer Ingelheim, AstraZeneca, Ono, Bayer, Pfizer Advisory Board, board of directors or other similar group.

Jan Baptiste Vermorken
Declared the receipt of honoraria and consultation fees from Merck and Amgen, o be member of Vaccinogen’s, PeJ biotech’s and Innate Pharma’s, advisory boards, board of directors or similar groups and declared the participation in a speaker bureau sponsored by Merck.

Sadamoto Zenda
Declared the participation in a speaker bureau sponsored by Merck.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 24 November 2016.

Ryuichi Hayashi
Tetsuhito Konishi
Minoru Sakuraba
All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED.

Our programmes are made possible thanks to educational grants received from: Aintree University Hospitals Foundation Trust, Association Radio-Clinique, Biogen, Hôpital Paul Brousse, Eli Lilly, Esaote, ESE Bioscientifica, Italfarmaco, Merck KGaA, Pfizer, Syiem, TOPEC Global, Université Catholique de Louvain (UCL), University of Pisa, University of Siena.